nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—CYP2D6—Lomustine—brain cancer	0.153	0.254	CbGbCtD
Levomilnacipran—CYP2D6—Hydroxyurea—brain cancer	0.116	0.193	CbGbCtD
Levomilnacipran—CYP3A4—Temozolomide—brain cancer	0.114	0.19	CbGbCtD
Levomilnacipran—CYP3A4—Lomustine—brain cancer	0.0973	0.162	CbGbCtD
Levomilnacipran—CYP2C8—Etoposide—brain cancer	0.058	0.0964	CbGbCtD
Levomilnacipran—ABCB1—Etoposide—brain cancer	0.0393	0.0652	CbGbCtD
Levomilnacipran—CYP3A4—Etoposide—brain cancer	0.0235	0.0391	CbGbCtD
Levomilnacipran—CYP2J2—Arachidonate Epoxygenase / Epoxide Hydrolase—CYP2C9—brain cancer	0.0194	0.141	CbGpPWpGaD
Levomilnacipran—CYP2J2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP2C9—brain cancer	0.0174	0.127	CbGpPWpGaD
Levomilnacipran—CYP2J2—Xenobiotics—CYP2C9—brain cancer	0.00836	0.0609	CbGpPWpGaD
Levomilnacipran—CYP2J2—blood vessel—brain cancer	0.0058	0.0875	CbGeAlD
Levomilnacipran—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—CYP2C9—brain cancer	0.00483	0.0352	CbGpPWpGaD
Levomilnacipran—CYP2C8—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP2C9—brain cancer	0.00434	0.0316	CbGpPWpGaD
Levomilnacipran—CYP2J2—Arachidonic acid metabolism—CYP2C9—brain cancer	0.00402	0.0292	CbGpPWpGaD
Levomilnacipran—CYP2C8—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP2C9—brain cancer	0.00395	0.0288	CbGpPWpGaD
Levomilnacipran—SLC6A4—ganglion—brain cancer	0.00393	0.0594	CbGeAlD
Levomilnacipran—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP2C9—brain cancer	0.00388	0.0282	CbGpPWpGaD
Levomilnacipran—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP2C9—brain cancer	0.00353	0.0257	CbGpPWpGaD
Levomilnacipran—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.00347	0.0253	CbGpPWpGaD
Levomilnacipran—SLC6A2—ganglion—brain cancer	0.00346	0.0523	CbGeAlD
Levomilnacipran—CYP2J2—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.00343	0.0249	CbGpPWpGaD
Levomilnacipran—CYP2C8—CYP2E1 reactions—CYP2C9—brain cancer	0.00337	0.0245	CbGpPWpGaD
Levomilnacipran—SLC6A4—Synaptic Vesicle Pathway—SYP—brain cancer	0.00336	0.0245	CbGpPWpGaD
Levomilnacipran—CYP2C19—CYP2E1 reactions—CYP2C9—brain cancer	0.00301	0.0219	CbGpPWpGaD
Levomilnacipran—SLC6A4—hindbrain—brain cancer	0.00298	0.045	CbGeAlD
Levomilnacipran—CYP2J2—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.00281	0.0205	CbGpPWpGaD
Levomilnacipran—CYP2J2—telencephalon—brain cancer	0.00281	0.0425	CbGeAlD
Levomilnacipran—CYP2D6—CYP2E1 reactions—CYP2C9—brain cancer	0.00276	0.0201	CbGpPWpGaD
Levomilnacipran—CYP2J2—pituitary gland—brain cancer	0.00229	0.0346	CbGeAlD
Levomilnacipran—CYP2J2—medulla oblongata—brain cancer	0.00221	0.0334	CbGeAlD
Levomilnacipran—CYP2C8—Xenobiotics—CYP2C9—brain cancer	0.00209	0.0152	CbGpPWpGaD
Levomilnacipran—CYP2J2—midbrain—brain cancer	0.00202	0.0305	CbGeAlD
Levomilnacipran—CYP2C8—Tamoxifen metabolism—CYP2C9—brain cancer	0.00201	0.0146	CbGpPWpGaD
Levomilnacipran—CYP2J2—spinal cord—brain cancer	0.00197	0.0298	CbGeAlD
Levomilnacipran—CYP2C19—Xenobiotics—CYP2C9—brain cancer	0.00186	0.0136	CbGpPWpGaD
Levomilnacipran—CYP2C19—Tamoxifen metabolism—CYP2C9—brain cancer	0.00179	0.013	CbGpPWpGaD
Levomilnacipran—CYP2J2—endocrine gland—brain cancer	0.00177	0.0268	CbGeAlD
Levomilnacipran—CYP2J2—head—brain cancer	0.00175	0.0264	CbGeAlD
Levomilnacipran—CYP2D6—Xenobiotics—CYP2C9—brain cancer	0.00171	0.0125	CbGpPWpGaD
Levomilnacipran—SLC6A4—brainstem—brain cancer	0.00171	0.0258	CbGeAlD
Levomilnacipran—Infection—Carboplatin—brain cancer	0.00169	0.00867	CcSEcCtD
Levomilnacipran—CYP2D6—Tamoxifen metabolism—CYP2C9—brain cancer	0.00165	0.012	CbGpPWpGaD
Levomilnacipran—Leukopenia—Lomustine—brain cancer	0.00163	0.00837	CcSEcCtD
Levomilnacipran—Angina pectoris—Procarbazine—brain cancer	0.00162	0.0083	CcSEcCtD
Levomilnacipran—Renal failure acute—Hydroxyurea—brain cancer	0.00161	0.00826	CcSEcCtD
Levomilnacipran—CYP2J2—central nervous system—brain cancer	0.0016	0.0241	CbGeAlD
Levomilnacipran—CYP2J2—cerebellum—brain cancer	0.00156	0.0236	CbGeAlD
Levomilnacipran—Pollakiuria—Procarbazine—brain cancer	0.00153	0.00787	CcSEcCtD
Levomilnacipran—SLC6A4—telencephalon—brain cancer	0.00152	0.0229	CbGeAlD
Levomilnacipran—SLC6A2—brainstem—brain cancer	0.0015	0.0227	CbGeAlD
Levomilnacipran—CYP2J2—Biological oxidations—CYP2C9—brain cancer	0.0015	0.0109	CbGpPWpGaD
Levomilnacipran—Dry eye—Temozolomide—brain cancer	0.00148	0.00758	CcSEcCtD
Levomilnacipran—Infection—Lomustine—brain cancer	0.00148	0.00758	CcSEcCtD
Levomilnacipran—CYP2J2—Metapathway biotransformation—CYP2C9—brain cancer	0.00147	0.0107	CbGpPWpGaD
Levomilnacipran—Thrombocytopenia—Lomustine—brain cancer	0.00145	0.00747	CcSEcCtD
Levomilnacipran—Chest discomfort—Etoposide—brain cancer	0.00145	0.00742	CcSEcCtD
Levomilnacipran—CYP2D6—hindbrain—brain cancer	0.00144	0.0217	CbGeAlD
Levomilnacipran—Anorexia—Lomustine—brain cancer	0.00142	0.00727	CcSEcCtD
Levomilnacipran—Haematuria—Procarbazine—brain cancer	0.00141	0.00724	CcSEcCtD
Levomilnacipran—Body temperature increased—Carboplatin—brain cancer	0.00134	0.0069	CcSEcCtD
Levomilnacipran—Breast disorder—Hydroxyurea—brain cancer	0.00134	0.00689	CcSEcCtD
Levomilnacipran—SLC6A2—telencephalon—brain cancer	0.00134	0.0202	CbGeAlD
Levomilnacipran—Hallucination—Procarbazine—brain cancer	0.00132	0.00678	CcSEcCtD
Levomilnacipran—Decreased appetite—Lomustine—brain cancer	0.00129	0.00663	CcSEcCtD
Levomilnacipran—CYP2C19—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.00128	0.00931	CbGpPWpGaD
Levomilnacipran—CYP2J2—brain—brain cancer	0.00127	0.0192	CbGeAlD
Levomilnacipran—ABCB1—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.00125	0.00909	CbGpPWpGaD
Levomilnacipran—Hot flush—Temozolomide—brain cancer	0.00124	0.00637	CcSEcCtD
Levomilnacipran—Flushing—Procarbazine—brain cancer	0.00123	0.00633	CcSEcCtD
Levomilnacipran—Menopausal symptoms—Temozolomide—brain cancer	0.00123	0.00632	CcSEcCtD
Levomilnacipran—Thirst—Temozolomide—brain cancer	0.00122	0.00626	CcSEcCtD
Levomilnacipran—Hyponatraemia—Carmustine—brain cancer	0.00121	0.00619	CcSEcCtD
Levomilnacipran—Dysuria—Hydroxyurea—brain cancer	0.0012	0.00617	CcSEcCtD
Levomilnacipran—Neutropenia—Hydroxyurea—brain cancer	0.0012	0.00617	CcSEcCtD
Levomilnacipran—Chills—Procarbazine—brain cancer	0.00119	0.00612	CcSEcCtD
Levomilnacipran—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.00119	0.00866	CbGpPWpGaD
Levomilnacipran—Body temperature increased—Lomustine—brain cancer	0.00117	0.00603	CcSEcCtD
Levomilnacipran—Tension—Procarbazine—brain cancer	0.00113	0.00583	CcSEcCtD
Levomilnacipran—CYP3A4—Xenobiotics—CYP2C9—brain cancer	0.00112	0.00815	CbGpPWpGaD
Levomilnacipran—SLC6A2—gonad—brain cancer	0.00111	0.0168	CbGeAlD
Levomilnacipran—Liver function test abnormal—Carmustine—brain cancer	0.00111	0.00569	CcSEcCtD
Levomilnacipran—SLC6A4—midbrain—brain cancer	0.00109	0.0164	CbGeAlD
Levomilnacipran—ABCB1—blood vessel—brain cancer	0.00108	0.0164	CbGeAlD
Levomilnacipran—Tremor—Procarbazine—brain cancer	0.00108	0.00556	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Hydroxyurea—brain cancer	0.00108	0.00556	CcSEcCtD
Levomilnacipran—CYP3A4—Tamoxifen metabolism—CYP2C9—brain cancer	0.00108	0.00784	CbGpPWpGaD
Levomilnacipran—Dry skin—Temozolomide—brain cancer	0.00106	0.00546	CcSEcCtD
Levomilnacipran—SLC6A4—spinal cord—brain cancer	0.00106	0.016	CbGeAlD
Levomilnacipran—SLC6A2—medulla oblongata—brain cancer	0.00105	0.0158	CbGeAlD
Levomilnacipran—Breast disorder—Temozolomide—brain cancer	0.00105	0.00539	CcSEcCtD
Levomilnacipran—Syncope—Procarbazine—brain cancer	0.00104	0.00532	CcSEcCtD
Levomilnacipran—Leukopenia—Procarbazine—brain cancer	0.00103	0.00531	CcSEcCtD
Levomilnacipran—Hallucination—Hydroxyurea—brain cancer	0.00102	0.00525	CcSEcCtD
Levomilnacipran—Loss of consciousness—Procarbazine—brain cancer	0.00102	0.00522	CcSEcCtD
Levomilnacipran—Abdominal distension—Temozolomide—brain cancer	0.00101	0.00519	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—HES5—brain cancer	0.00101	0.00734	CbGpPWpGaD
Levomilnacipran—CYP2C8—Arachidonic acid metabolism—CYP2C9—brain cancer	0.001	0.0073	CbGpPWpGaD
Levomilnacipran—Convulsion—Procarbazine—brain cancer	0.001	0.00514	CcSEcCtD
Levomilnacipran—Hypertension—Procarbazine—brain cancer	0.000998	0.00512	CcSEcCtD
Levomilnacipran—Anxiety—Procarbazine—brain cancer	0.00098	0.00504	CcSEcCtD
Levomilnacipran—Neutropenia—Carmustine—brain cancer	0.00097	0.00498	CcSEcCtD
Levomilnacipran—Dry mouth—Procarbazine—brain cancer	0.000962	0.00494	CcSEcCtD
Levomilnacipran—SLC6A4—endocrine gland—brain cancer	0.000957	0.0144	CbGeAlD
Levomilnacipran—SLC6A4—head—brain cancer	0.000945	0.0143	CbGeAlD
Levomilnacipran—Vomiting—Lomustine—brain cancer	0.000944	0.00485	CcSEcCtD
Levomilnacipran—Dysuria—Temozolomide—brain cancer	0.000938	0.00482	CcSEcCtD
Levomilnacipran—Neutropenia—Temozolomide—brain cancer	0.000938	0.00482	CcSEcCtD
Levomilnacipran—Infection—Procarbazine—brain cancer	0.000937	0.00481	CcSEcCtD
Levomilnacipran—Angiopathy—Hydroxyurea—brain cancer	0.000932	0.00479	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Temozolomide—brain cancer	0.000932	0.00479	CcSEcCtD
Levomilnacipran—Shock—Procarbazine—brain cancer	0.000928	0.00477	CcSEcCtD
Levomilnacipran—Pollakiuria—Temozolomide—brain cancer	0.000926	0.00476	CcSEcCtD
Levomilnacipran—Erectile dysfunction—Temozolomide—brain cancer	0.000923	0.00474	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Procarbazine—brain cancer	0.000923	0.00474	CcSEcCtD
Levomilnacipran—Chills—Hydroxyurea—brain cancer	0.000922	0.00474	CcSEcCtD
Levomilnacipran—Tachycardia—Procarbazine—brain cancer	0.00092	0.00473	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Procarbazine—brain cancer	0.000912	0.00468	CcSEcCtD
Levomilnacipran—Weight decreased—Temozolomide—brain cancer	0.000907	0.00466	CcSEcCtD
Levomilnacipran—Urinary tract infection—Carmustine—brain cancer	0.000899	0.00462	CcSEcCtD
Levomilnacipran—Anorexia—Procarbazine—brain cancer	0.000899	0.00462	CcSEcCtD
Levomilnacipran—CYP2C19—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000895	0.00652	CbGpPWpGaD
Levomilnacipran—CYP2C8—pituitary gland—brain cancer	0.000893	0.0135	CbGeAlD
Levomilnacipran—Stevens-Johnson syndrome—Temozolomide—brain cancer	0.000886	0.00455	CcSEcCtD
Levomilnacipran—Nausea—Lomustine—brain cancer	0.000882	0.00453	CcSEcCtD
Levomilnacipran—Hypotension—Procarbazine—brain cancer	0.000881	0.00453	CcSEcCtD
Levomilnacipran—Urinary tract infection—Temozolomide—brain cancer	0.000869	0.00446	CcSEcCtD
Levomilnacipran—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000867	0.00631	CbGpPWpGaD
Levomilnacipran—SLC6A4—central nervous system—brain cancer	0.000862	0.013	CbGeAlD
Levomilnacipran—CYP2C8—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000855	0.00623	CbGpPWpGaD
Levomilnacipran—Insomnia—Procarbazine—brain cancer	0.000853	0.00438	CcSEcCtD
Levomilnacipran—SLC6A4—Circadian rythm related genes—NTRK3—brain cancer	0.000851	0.00619	CbGpPWpGaD
Levomilnacipran—Paraesthesia—Procarbazine—brain cancer	0.000847	0.00435	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Temozolomide—brain cancer	0.000845	0.00434	CcSEcCtD
Levomilnacipran—SLC6A2—endocrine gland—brain cancer	0.000842	0.0127	CbGeAlD
Levomilnacipran—Somnolence—Procarbazine—brain cancer	0.000838	0.00431	CcSEcCtD
Levomilnacipran—SLC6A2—head—brain cancer	0.000832	0.0126	CbGeAlD
Levomilnacipran—Hypoaesthesia—Carmustine—brain cancer	0.000826	0.00424	CcSEcCtD
Levomilnacipran—Hallucination—Carmustine—brain cancer	0.000826	0.00424	CcSEcCtD
Levomilnacipran—CYP2D6—brainstem—brain cancer	0.000824	0.0124	CbGeAlD
Levomilnacipran—Decreased appetite—Procarbazine—brain cancer	0.00082	0.00421	CcSEcCtD
Levomilnacipran—Oedema peripheral—Carmustine—brain cancer	0.000818	0.0042	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Carmustine—brain cancer	0.000816	0.00419	CcSEcCtD
Levomilnacipran—Fatigue—Procarbazine—brain cancer	0.000813	0.00418	CcSEcCtD
Levomilnacipran—Constipation—Procarbazine—brain cancer	0.000806	0.00414	CcSEcCtD
Levomilnacipran—Hepatitis—Temozolomide—brain cancer	0.000803	0.00412	CcSEcCtD
Levomilnacipran—Leukopenia—Hydroxyurea—brain cancer	0.0008	0.00411	CcSEcCtD
Levomilnacipran—Hallucination—Temozolomide—brain cancer	0.000798	0.0041	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Temozolomide—brain cancer	0.000798	0.0041	CcSEcCtD
Levomilnacipran—CYP2C19—endocrine gland—brain cancer	0.000793	0.012	CbGeAlD
Levomilnacipran—Urinary tract disorder—Temozolomide—brain cancer	0.000793	0.00407	CcSEcCtD
Levomilnacipran—Oedema peripheral—Temozolomide—brain cancer	0.000791	0.00406	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Temozolomide—brain cancer	0.000789	0.00405	CcSEcCtD
Levomilnacipran—Urethral disorder—Temozolomide—brain cancer	0.000787	0.00404	CcSEcCtD
Levomilnacipran—Eye disorder—Carmustine—brain cancer	0.000776	0.00399	CcSEcCtD
Levomilnacipran—Convulsion—Hydroxyurea—brain cancer	0.000775	0.00398	CcSEcCtD
Levomilnacipran—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000774	0.00563	CbGpPWpGaD
Levomilnacipran—Gastrointestinal pain—Procarbazine—brain cancer	0.000771	0.00396	CcSEcCtD
Levomilnacipran—Flushing—Carmustine—brain cancer	0.000771	0.00396	CcSEcCtD
Levomilnacipran—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000769	0.0056	CbGpPWpGaD
Levomilnacipran—CYP2C19—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000764	0.00556	CbGpPWpGaD
Levomilnacipran—SLC6A2—central nervous system—brain cancer	0.000759	0.0115	CbGeAlD
Levomilnacipran—Erythema multiforme—Temozolomide—brain cancer	0.000759	0.0039	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000756	0.00388	CcSEcCtD
Levomilnacipran—Neutropenia—Etoposide—brain cancer	0.00075	0.00385	CcSEcCtD
Levomilnacipran—Eye disorder—Temozolomide—brain cancer	0.00075	0.00385	CcSEcCtD
Levomilnacipran—Urticaria—Procarbazine—brain cancer	0.000749	0.00385	CcSEcCtD
Levomilnacipran—Body temperature increased—Procarbazine—brain cancer	0.000745	0.00383	CcSEcCtD
Levomilnacipran—Abdominal pain—Procarbazine—brain cancer	0.000745	0.00383	CcSEcCtD
Levomilnacipran—Flushing—Temozolomide—brain cancer	0.000745	0.00383	CcSEcCtD
Levomilnacipran—Cardiac disorder—Temozolomide—brain cancer	0.000745	0.00383	CcSEcCtD
Levomilnacipran—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000733	0.00533	CbGpPWpGaD
Levomilnacipran—CYP2D6—telencephalon—brain cancer	0.000731	0.011	CbGeAlD
Levomilnacipran—Angiopathy—Temozolomide—brain cancer	0.000728	0.00374	CcSEcCtD
Levomilnacipran—Mental disorder—Carmustine—brain cancer	0.000728	0.00374	CcSEcCtD
Levomilnacipran—Infection—Hydroxyurea—brain cancer	0.000725	0.00372	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Temozolomide—brain cancer	0.000723	0.00372	CcSEcCtD
Levomilnacipran—Malnutrition—Carmustine—brain cancer	0.000723	0.00371	CcSEcCtD
Levomilnacipran—Chills—Temozolomide—brain cancer	0.00072	0.0037	CcSEcCtD
Levomilnacipran—Nervous system disorder—Hydroxyurea—brain cancer	0.000716	0.00368	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Hydroxyurea—brain cancer	0.000715	0.00367	CcSEcCtD
Levomilnacipran—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000712	0.00518	CbGpPWpGaD
Levomilnacipran—Stevens-Johnson syndrome—Etoposide—brain cancer	0.000709	0.00364	CcSEcCtD
Levomilnacipran—Skin disorder—Hydroxyurea—brain cancer	0.000709	0.00364	CcSEcCtD
Levomilnacipran—Mental disorder—Temozolomide—brain cancer	0.000703	0.00361	CcSEcCtD
Levomilnacipran—CYP2C8—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000703	0.00511	CbGpPWpGaD
Levomilnacipran—CYP2D6—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000702	0.00511	CbGpPWpGaD
Levomilnacipran—Malnutrition—Temozolomide—brain cancer	0.000699	0.00359	CcSEcCtD
Levomilnacipran—Anorexia—Hydroxyurea—brain cancer	0.000696	0.00357	CcSEcCtD
Levomilnacipran—Hypersensitivity—Procarbazine—brain cancer	0.000695	0.00357	CcSEcCtD
Levomilnacipran—CYP2C8—endocrine gland—brain cancer	0.000692	0.0104	CbGeAlD
Levomilnacipran—SLC6A4—brain—brain cancer	0.000685	0.0103	CbGeAlD
Levomilnacipran—Dysgeusia—Temozolomide—brain cancer	0.000684	0.00351	CcSEcCtD
Levomilnacipran—Vision blurred—Carmustine—brain cancer	0.000681	0.0035	CcSEcCtD
Levomilnacipran—Tremor—Carmustine—brain cancer	0.000677	0.00348	CcSEcCtD
Levomilnacipran—Asthenia—Procarbazine—brain cancer	0.000677	0.00348	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Etoposide—brain cancer	0.000677	0.00348	CcSEcCtD
Levomilnacipran—Pruritus—Procarbazine—brain cancer	0.000667	0.00343	CcSEcCtD
Levomilnacipran—Agitation—Carmustine—brain cancer	0.000664	0.00341	CcSEcCtD
Levomilnacipran—Vision blurred—Temozolomide—brain cancer	0.000658	0.00338	CcSEcCtD
Levomilnacipran—Tremor—Temozolomide—brain cancer	0.000655	0.00336	CcSEcCtD
Levomilnacipran—Dyspnoea—Hydroxyurea—brain cancer	0.000651	0.00334	CcSEcCtD
Levomilnacipran—Somnolence—Hydroxyurea—brain cancer	0.000649	0.00333	CcSEcCtD
Levomilnacipran—Leukopenia—Carmustine—brain cancer	0.000647	0.00332	CcSEcCtD
Levomilnacipran—Diarrhoea—Procarbazine—brain cancer	0.000645	0.00331	CcSEcCtD
Levomilnacipran—Dyspepsia—Hydroxyurea—brain cancer	0.000642	0.0033	CcSEcCtD
Levomilnacipran—Agitation—Temozolomide—brain cancer	0.000642	0.0033	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Etoposide—brain cancer	0.000639	0.00328	CcSEcCtD
Levomilnacipran—Decreased appetite—Hydroxyurea—brain cancer	0.000634	0.00326	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Etoposide—brain cancer	0.000634	0.00326	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.00063	0.00324	CcSEcCtD
Levomilnacipran—Urethral disorder—Etoposide—brain cancer	0.000629	0.00323	CcSEcCtD
Levomilnacipran—Fatigue—Hydroxyurea—brain cancer	0.000629	0.00323	CcSEcCtD
Levomilnacipran—CYP2C19—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000627	0.00456	CbGpPWpGaD
Levomilnacipran—Convulsion—Carmustine—brain cancer	0.000626	0.00322	CcSEcCtD
Levomilnacipran—Leukopenia—Temozolomide—brain cancer	0.000625	0.00321	CcSEcCtD
Levomilnacipran—Hypertension—Carmustine—brain cancer	0.000624	0.00321	CcSEcCtD
Levomilnacipran—Constipation—Hydroxyurea—brain cancer	0.000624	0.00321	CcSEcCtD
Levomilnacipran—Dizziness—Procarbazine—brain cancer	0.000624	0.0032	CcSEcCtD
Levomilnacipran—Palpitations—Temozolomide—brain cancer	0.000617	0.00317	CcSEcCtD
Levomilnacipran—Chest pain—Carmustine—brain cancer	0.000615	0.00316	CcSEcCtD
Levomilnacipran—Anxiety—Carmustine—brain cancer	0.000613	0.00315	CcSEcCtD
Levomilnacipran—Erythema multiforme—Etoposide—brain cancer	0.000607	0.00312	CcSEcCtD
Levomilnacipran—Convulsion—Temozolomide—brain cancer	0.000605	0.00311	CcSEcCtD
Levomilnacipran—Hypertension—Temozolomide—brain cancer	0.000603	0.0031	CcSEcCtD
Levomilnacipran—SLC6A2—brain—brain cancer	0.000603	0.0091	CbGeAlD
Levomilnacipran—Eye disorder—Etoposide—brain cancer	0.0006	0.00308	CcSEcCtD
Levomilnacipran—Vomiting—Procarbazine—brain cancer	0.0006	0.00308	CcSEcCtD
Levomilnacipran—Flushing—Etoposide—brain cancer	0.000596	0.00306	CcSEcCtD
Levomilnacipran—Cardiac disorder—Etoposide—brain cancer	0.000596	0.00306	CcSEcCtD
Levomilnacipran—Rash—Procarbazine—brain cancer	0.000595	0.00305	CcSEcCtD
Levomilnacipran—Dermatitis—Procarbazine—brain cancer	0.000594	0.00305	CcSEcCtD
Levomilnacipran—Anxiety—Temozolomide—brain cancer	0.000593	0.00304	CcSEcCtD
Levomilnacipran—Headache—Procarbazine—brain cancer	0.000591	0.00304	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000591	0.00303	CcSEcCtD
Levomilnacipran—Infection—Carmustine—brain cancer	0.000586	0.00301	CcSEcCtD
Levomilnacipran—Angiopathy—Etoposide—brain cancer	0.000583	0.00299	CcSEcCtD
Levomilnacipran—Dry mouth—Temozolomide—brain cancer	0.000582	0.00299	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Etoposide—brain cancer	0.000579	0.00297	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Carmustine—brain cancer	0.000578	0.00297	CcSEcCtD
Levomilnacipran—Body temperature increased—Hydroxyurea—brain cancer	0.000577	0.00296	CcSEcCtD
Levomilnacipran—CYP2D6—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000577	0.0042	CbGpPWpGaD
Levomilnacipran—Chills—Etoposide—brain cancer	0.000576	0.00296	CcSEcCtD
Levomilnacipran—Tachycardia—Carmustine—brain cancer	0.000576	0.00296	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	0.000574	0.00418	CbGpPWpGaD
Levomilnacipran—Infection—Temozolomide—brain cancer	0.000566	0.00291	CcSEcCtD
Levomilnacipran—Anorexia—Carmustine—brain cancer	0.000562	0.00289	CcSEcCtD
Levomilnacipran—Nausea—Procarbazine—brain cancer	0.00056	0.00288	CcSEcCtD
Levomilnacipran—Nervous system disorder—Temozolomide—brain cancer	0.000559	0.00287	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Temozolomide—brain cancer	0.000558	0.00287	CcSEcCtD
Levomilnacipran—Skin disorder—Temozolomide—brain cancer	0.000554	0.00285	CcSEcCtD
Levomilnacipran—Hypotension—Carmustine—brain cancer	0.000551	0.00283	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Temozolomide—brain cancer	0.000551	0.00283	CcSEcCtD
Levomilnacipran—Dysgeusia—Etoposide—brain cancer	0.000547	0.00281	CcSEcCtD
Levomilnacipran—Anorexia—Temozolomide—brain cancer	0.000543	0.00279	CcSEcCtD
Levomilnacipran—Hypersensitivity—Hydroxyurea—brain cancer	0.000538	0.00276	CcSEcCtD
Levomilnacipran—Insomnia—Carmustine—brain cancer	0.000534	0.00274	CcSEcCtD
Levomilnacipran—Paraesthesia—Carmustine—brain cancer	0.00053	0.00272	CcSEcCtD
Levomilnacipran—ABCB1—telencephalon—brain cancer	0.000526	0.00794	CbGeAlD
Levomilnacipran—Dyspnoea—Carmustine—brain cancer	0.000526	0.0027	CcSEcCtD
Levomilnacipran—Somnolence—Carmustine—brain cancer	0.000524	0.00269	CcSEcCtD
Levomilnacipran—Asthenia—Hydroxyurea—brain cancer	0.000524	0.00269	CcSEcCtD
Levomilnacipran—Insomnia—Temozolomide—brain cancer	0.000516	0.00265	CcSEcCtD
Levomilnacipran—Decreased appetite—Carmustine—brain cancer	0.000513	0.00263	CcSEcCtD
Levomilnacipran—Paraesthesia—Temozolomide—brain cancer	0.000512	0.00263	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Carmustine—brain cancer	0.000509	0.00262	CcSEcCtD
Levomilnacipran—Dyspnoea—Temozolomide—brain cancer	0.000508	0.00261	CcSEcCtD
Levomilnacipran—Somnolence—Temozolomide—brain cancer	0.000507	0.0026	CcSEcCtD
Levomilnacipran—Constipation—Carmustine—brain cancer	0.000505	0.00259	CcSEcCtD
Levomilnacipran—Dyspepsia—Temozolomide—brain cancer	0.000502	0.00258	CcSEcCtD
Levomilnacipran—Leukopenia—Etoposide—brain cancer	0.0005	0.00257	CcSEcCtD
Levomilnacipran—Diarrhoea—Hydroxyurea—brain cancer	0.000499	0.00257	CcSEcCtD
Levomilnacipran—Decreased appetite—Temozolomide—brain cancer	0.000496	0.00255	CcSEcCtD
Levomilnacipran—CYP2C8—brain—brain cancer	0.000495	0.00747	CbGeAlD
Levomilnacipran—Gastrointestinal disorder—Temozolomide—brain cancer	0.000492	0.00253	CcSEcCtD
Levomilnacipran—Fatigue—Temozolomide—brain cancer	0.000492	0.00253	CcSEcCtD
Levomilnacipran—Loss of consciousness—Etoposide—brain cancer	0.000491	0.00252	CcSEcCtD
Levomilnacipran—Constipation—Temozolomide—brain cancer	0.000488	0.0025	CcSEcCtD
Levomilnacipran—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—SKP2—brain cancer	0.000487	0.00354	CbGpPWpGaD
Levomilnacipran—Convulsion—Etoposide—brain cancer	0.000484	0.00249	CcSEcCtD
Levomilnacipran—Hypertension—Etoposide—brain cancer	0.000483	0.00248	CcSEcCtD
Levomilnacipran—Dizziness—Hydroxyurea—brain cancer	0.000483	0.00248	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Carmustine—brain cancer	0.000482	0.00248	CcSEcCtD
Levomilnacipran—Chest pain—Etoposide—brain cancer	0.000476	0.00244	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000473	0.00243	CcSEcCtD
Levomilnacipran—CYP3A4—endocrine gland—brain cancer	0.000469	0.00707	CbGeAlD
Levomilnacipran—Abdominal pain—Carmustine—brain cancer	0.000466	0.0024	CcSEcCtD
Levomilnacipran—Body temperature increased—Carmustine—brain cancer	0.000466	0.0024	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Temozolomide—brain cancer	0.000466	0.0024	CcSEcCtD
Levomilnacipran—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000465	0.00339	CbGpPWpGaD
Levomilnacipran—Vomiting—Hydroxyurea—brain cancer	0.000464	0.00238	CcSEcCtD
Levomilnacipran—CYP2D6—endocrine gland—brain cancer	0.000461	0.00696	CbGeAlD
Levomilnacipran—Rash—Hydroxyurea—brain cancer	0.00046	0.00236	CcSEcCtD
Levomilnacipran—Dermatitis—Hydroxyurea—brain cancer	0.00046	0.00236	CcSEcCtD
Levomilnacipran—CYP3A4—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000459	0.00334	CbGpPWpGaD
Levomilnacipran—Headache—Hydroxyurea—brain cancer	0.000457	0.00235	CcSEcCtD
Levomilnacipran—CYP2D6—head—brain cancer	0.000455	0.00687	CbGeAlD
Levomilnacipran—Infection—Etoposide—brain cancer	0.000453	0.00233	CcSEcCtD
Levomilnacipran—Urticaria—Temozolomide—brain cancer	0.000453	0.00233	CcSEcCtD
Levomilnacipran—Abdominal pain—Temozolomide—brain cancer	0.000451	0.00232	CcSEcCtD
Levomilnacipran—Body temperature increased—Temozolomide—brain cancer	0.000451	0.00232	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Etoposide—brain cancer	0.000447	0.00229	CcSEcCtD
Levomilnacipran—Tachycardia—Etoposide—brain cancer	0.000445	0.00229	CcSEcCtD
Levomilnacipran—Skin disorder—Etoposide—brain cancer	0.000443	0.00228	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Etoposide—brain cancer	0.000441	0.00227	CcSEcCtD
Levomilnacipran—ABCB1—gonad—brain cancer	0.000439	0.00663	CbGeAlD
Levomilnacipran—Anorexia—Etoposide—brain cancer	0.000435	0.00223	CcSEcCtD
Levomilnacipran—Hypersensitivity—Carmustine—brain cancer	0.000435	0.00223	CcSEcCtD
Levomilnacipran—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDK6—brain cancer	0.000434	0.00316	CbGpPWpGaD
Levomilnacipran—Nausea—Hydroxyurea—brain cancer	0.000434	0.00223	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—ESR2—brain cancer	0.000429	0.00313	CbGpPWpGaD
Levomilnacipran—ABCB1—pituitary gland—brain cancer	0.000428	0.00646	CbGeAlD
Levomilnacipran—Hypotension—Etoposide—brain cancer	0.000426	0.00219	CcSEcCtD
Levomilnacipran—Asthenia—Carmustine—brain cancer	0.000423	0.00217	CcSEcCtD
Levomilnacipran—CYP3A4—central nervous system—brain cancer	0.000422	0.00637	CbGeAlD
Levomilnacipran—Hypersensitivity—Temozolomide—brain cancer	0.00042	0.00216	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	0.00042	0.00306	CbGpPWpGaD
Levomilnacipran—CYP2D6—central nervous system—brain cancer	0.000416	0.00627	CbGeAlD
Levomilnacipran—ABCB1—medulla oblongata—brain cancer	0.000413	0.00624	CbGeAlD
Levomilnacipran—Paraesthesia—Etoposide—brain cancer	0.00041	0.0021	CcSEcCtD
Levomilnacipran—Asthenia—Temozolomide—brain cancer	0.000409	0.0021	CcSEcCtD
Levomilnacipran—Dyspnoea—Etoposide—brain cancer	0.000407	0.00209	CcSEcCtD
Levomilnacipran—CYP2D6—cerebellum—brain cancer	0.000406	0.00613	CbGeAlD
Levomilnacipran—Somnolence—Etoposide—brain cancer	0.000406	0.00208	CcSEcCtD
Levomilnacipran—Diarrhoea—Carmustine—brain cancer	0.000404	0.00207	CcSEcCtD
Levomilnacipran—Pruritus—Temozolomide—brain cancer	0.000403	0.00207	CcSEcCtD
Levomilnacipran—Decreased appetite—Etoposide—brain cancer	0.000397	0.00204	CcSEcCtD
Levomilnacipran—CYP3A4—Irinotecan Pathway—APC—brain cancer	0.000395	0.00288	CbGpPWpGaD
Levomilnacipran—Gastrointestinal disorder—Etoposide—brain cancer	0.000394	0.00202	CcSEcCtD
Levomilnacipran—Fatigue—Etoposide—brain cancer	0.000393	0.00202	CcSEcCtD
Levomilnacipran—Dizziness—Carmustine—brain cancer	0.00039	0.002	CcSEcCtD
Levomilnacipran—Constipation—Etoposide—brain cancer	0.00039	0.002	CcSEcCtD
Levomilnacipran—Diarrhoea—Temozolomide—brain cancer	0.00039	0.002	CcSEcCtD
Levomilnacipran—ABCB1—midbrain—brain cancer	0.000378	0.0057	CbGeAlD
Levomilnacipran—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000377	0.00275	CbGpPWpGaD
Levomilnacipran—Dizziness—Temozolomide—brain cancer	0.000377	0.00194	CcSEcCtD
Levomilnacipran—Vomiting—Carmustine—brain cancer	0.000375	0.00193	CcSEcCtD
Levomilnacipran—CYP2C8—Biological oxidations—CYP2C9—brain cancer	0.000373	0.00272	CbGpPWpGaD
Levomilnacipran—Gastrointestinal pain—Etoposide—brain cancer	0.000373	0.00192	CcSEcCtD
Levomilnacipran—Rash—Carmustine—brain cancer	0.000372	0.00191	CcSEcCtD
Levomilnacipran—Dermatitis—Carmustine—brain cancer	0.000372	0.00191	CcSEcCtD
Levomilnacipran—Headache—Carmustine—brain cancer	0.00037	0.0019	CcSEcCtD
Levomilnacipran—ABCB1—spinal cord—brain cancer	0.000369	0.00556	CbGeAlD
Levomilnacipran—CYP2C8—Metapathway biotransformation—CYP2C9—brain cancer	0.000368	0.00268	CbGpPWpGaD
Levomilnacipran—Vomiting—Temozolomide—brain cancer	0.000363	0.00186	CcSEcCtD
Levomilnacipran—Urticaria—Etoposide—brain cancer	0.000362	0.00186	CcSEcCtD
Levomilnacipran—Abdominal pain—Etoposide—brain cancer	0.000361	0.00185	CcSEcCtD
Levomilnacipran—Body temperature increased—Etoposide—brain cancer	0.000361	0.00185	CcSEcCtD
Levomilnacipran—Rash—Temozolomide—brain cancer	0.000359	0.00185	CcSEcCtD
Levomilnacipran—Dermatitis—Temozolomide—brain cancer	0.000359	0.00185	CcSEcCtD
Levomilnacipran—Headache—Temozolomide—brain cancer	0.000357	0.00183	CcSEcCtD
Levomilnacipran—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—brain cancer	0.00035	0.00255	CbGpPWpGaD
Levomilnacipran—Nausea—Carmustine—brain cancer	0.00035	0.0018	CcSEcCtD
Levomilnacipran—Nausea—Temozolomide—brain cancer	0.000339	0.00174	CcSEcCtD
Levomilnacipran—Hypersensitivity—Etoposide—brain cancer	0.000336	0.00173	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—HES1—brain cancer	0.000333	0.00243	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—CYP2C9—brain cancer	0.000333	0.00242	CbGpPWpGaD
Levomilnacipran—ABCB1—endocrine gland—brain cancer	0.000332	0.00501	CbGeAlD
Levomilnacipran—CYP2D6—brain—brain cancer	0.00033	0.00498	CbGeAlD
Levomilnacipran—CYP2C19—Metapathway biotransformation—CYP2C9—brain cancer	0.000329	0.00239	CbGpPWpGaD
Levomilnacipran—ABCB1—head—brain cancer	0.000328	0.00494	CbGeAlD
Levomilnacipran—Asthenia—Etoposide—brain cancer	0.000327	0.00168	CcSEcCtD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—S100A10—brain cancer	0.000325	0.00237	CbGpPWpGaD
Levomilnacipran—Pruritus—Etoposide—brain cancer	0.000323	0.00166	CcSEcCtD
Levomilnacipran—Diarrhoea—Etoposide—brain cancer	0.000312	0.0016	CcSEcCtD
Levomilnacipran—CYP2D6—Biological oxidations—CYP2C9—brain cancer	0.000306	0.00223	CbGpPWpGaD
Levomilnacipran—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—brain cancer	0.000304	0.00221	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—CYP2C9—brain cancer	0.000302	0.0022	CbGpPWpGaD
Levomilnacipran—Dizziness—Etoposide—brain cancer	0.000302	0.00155	CcSEcCtD
Levomilnacipran—ABCB1—central nervous system—brain cancer	0.000299	0.00451	CbGeAlD
Levomilnacipran—ABCB1—cerebellum—brain cancer	0.000292	0.00441	CbGeAlD
Levomilnacipran—Vomiting—Etoposide—brain cancer	0.00029	0.00149	CcSEcCtD
Levomilnacipran—Rash—Etoposide—brain cancer	0.000288	0.00148	CcSEcCtD
Levomilnacipran—Dermatitis—Etoposide—brain cancer	0.000287	0.00148	CcSEcCtD
Levomilnacipran—Headache—Etoposide—brain cancer	0.000286	0.00147	CcSEcCtD
Levomilnacipran—SLC6A4—Circadian rythm related genes—SIRT1—brain cancer	0.000282	0.00206	CbGpPWpGaD
Levomilnacipran—Nausea—Etoposide—brain cancer	0.000271	0.00139	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—CYP2C9—brain cancer	0.000256	0.00186	CbGpPWpGaD
Levomilnacipran—ABCB1—brain—brain cancer	0.000237	0.00358	CbGeAlD
Levomilnacipran—CYP2J2—Metabolism—BSG—brain cancer	0.000217	0.00158	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—CDK4—brain cancer	0.000214	0.00155	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—PDGFRA—brain cancer	0.000207	0.00151	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—CYP2C9—brain cancer	0.0002	0.00146	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP2C9—brain cancer	0.000198	0.00144	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—IDH1—brain cancer	0.000187	0.00136	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—brain cancer	0.000173	0.00126	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—brain cancer	0.000167	0.00122	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—brain cancer	0.000164	0.00119	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	0.000152	0.00111	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—TRPC6—brain cancer	0.00015	0.00109	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—ENO2—brain cancer	0.000148	0.00108	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—VEGFA—brain cancer	0.000147	0.00107	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	0.000143	0.00104	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—S100A10—brain cancer	0.000143	0.00104	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—brain cancer	0.000138	0.00101	CbGpPWpGaD
Levomilnacipran—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—brain cancer	0.00013	0.000943	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	0.000128	0.000931	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—brain cancer	0.000114	0.000827	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—IL2—brain cancer	0.000113	0.000823	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—SIRT1—brain cancer	0.000111	0.000811	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—VEGFA—brain cancer	0.000111	0.000808	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—brain cancer	0.00011	0.000801	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—IDH1—brain cancer	0.000105	0.000763	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—brain cancer	0.000102	0.000744	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—brain cancer	9.74e-05	0.000709	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—VEGFA—brain cancer	9.61e-05	0.000699	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—IDH1—brain cancer	9.35e-05	0.000681	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—TP53—brain cancer	9.08e-05	0.000661	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	8.42e-05	0.000613	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—APC—brain cancer	7.93e-05	0.000577	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PIK3CG—brain cancer	6.78e-05	0.000493	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—TRPC6—brain cancer	6.62e-05	0.000482	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP2C9—brain cancer	6.38e-05	0.000465	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	6.16e-05	0.000448	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP2C9—brain cancer	5.7e-05	0.000415	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP2C9—brain cancer	5.56e-05	0.000405	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	5.44e-05	0.000396	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—BSG—brain cancer	5.43e-05	0.000395	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	5.39e-05	0.000392	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP2C9—brain cancer	5.24e-05	0.000381	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—BSG—brain cancer	4.84e-05	0.000353	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	4.74e-05	0.000345	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—BSG—brain cancer	4.73e-05	0.000344	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—IDH1—brain cancer	4.67e-05	0.00034	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—BSG—brain cancer	4.46e-05	0.000324	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	4.36e-05	0.000318	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	4.27e-05	0.000311	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—IDH1—brain cancer	4.17e-05	0.000303	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—IDH1—brain cancer	4.07e-05	0.000296	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—IDH1—brain cancer	3.83e-05	0.000279	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	3.8e-05	0.000277	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ENO2—brain cancer	3.69e-05	0.000269	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	3.58e-05	0.000261	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP2C9—brain cancer	3.43e-05	0.000249	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	3.39e-05	0.000247	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ENO2—brain cancer	3.29e-05	0.00024	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ENO2—brain cancer	3.21e-05	0.000234	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ENO2—brain cancer	3.03e-05	0.00022	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—BSG—brain cancer	2.91e-05	0.000212	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—IDH1—brain cancer	2.51e-05	0.000182	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ENO2—brain cancer	1.98e-05	0.000144	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CG—brain cancer	1.69e-05	0.000123	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CG—brain cancer	1.51e-05	0.00011	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CG—brain cancer	1.47e-05	0.000107	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CG—brain cancer	1.39e-05	0.000101	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CG—brain cancer	9.08e-06	6.61e-05	CbGpPWpGaD
